Cargando…
Five-Year Cancer Epidemiology at the National Referral Hospital: Hospital-Based Cancer Registry Data in Indonesia
In 2016, there were 1,308,061 cases of cancer being treated in Indonesia, with 2.2 trillion rupiahs spent, amounting to $486,960,633 in US dollars (purchasing power parity 2016). The high burden of cancers in Indonesia requires a valid data collection to inform future cancer-related policies. The pu...
Autores principales: | Gondhowiardjo, Soehartati, Christina, Nadia, Ganapati, Ngakan P.D., Hawariy, Salik, Radityamurti, Fahmi, Jayalie, Vito F., Octavianus, Steven, Prawira Putra, Andre, Sekarutami, Sri M., Prajogi, Gregorius B., Giselvania, Angela, Adham, Marlinda, Hamid, Agus R.A.H., Widyastuti, Endang, Prabowo, Yogi, Aninditha, Tiara, Purwoto, Gatot, Aman, Renindra A., Siregar, Trifona P., Siswoyo, Alvita Dewi, Lisnawati, Handjari, Diah R., Atmakusuma, Djumhana, Rajabto, Wulyo, Mulansari, Nadia A., Ratna, Nurul, Pitoyo, Ceva W., Panigoro, Sonar Soni, Kartini, Diani, Yulian, Erwin D., Andrisa, Rossalyn S., Jeo, Wifanto S., Wardhani, Rizky K., Tambunan, Tresia F.U., Agianda, Feranindhya, Priyambodho |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081513/ https://www.ncbi.nlm.nih.gov/pubmed/33539173 http://dx.doi.org/10.1200/GO.20.00155 |
Ejemplares similares
-
Achievement of Pre- and Post-Transfusion Hemoglobin Levels in Adult Transfusion-Dependent Beta Thalassemia: Associated Factors and Relationship to Reduction of Spleen Enlargement
por: Atmakusuma, Tubagus Djumhana, et al.
Publicado: (2021) -
Primary CD20‐positive mediastinal diffuse large B‐cell lymphoma
por: Rajabto, Wulyo, et al.
Publicado: (2020) -
History and growth of radiation oncology in Indonesia
por: Gondhowiardjo, SA, et al.
Publicado: (2008) -
A comparative study of the COVID-19 vaccine efficacy among cancer patients: mRNA versus non-mRNA
por: Rachman, Andhika, et al.
Publicado: (2023) -
The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19
por: Rajabto, Wulyo, et al.
Publicado: (2022)